Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of primary immunodeficiency (acc. WHO)~* Previous treatment with commercial Octagam 5% every 3-4 weeks for at least 6 infusions intervals~* Documented IgG trough levels of the two previous infusions before enrollment with a value of at least 5.5 g/L for both~Exclusion Criteria:~* Acute infection requiring intravenous antibiotic treatment within two weeks before screening~* Exposure to blood or any blood product or derivative other than commercially available Octagam 5%, within the past 3 months~* History of hypersensitivity to blood or plasma derived products~* Requirement of any routine premedication for IGIV treatment~* History of congenital impairment of pulmonary function~* Severe liver function impairment~* Severe renal function impairment or predisposition for acute renal failure~* History of autoimmune haemolytic anaemia~* History of diabetes mellitus~* Congestive heart failure NYHA III or IV~* Non-controlled arterial hypertension~* History of DVT or thrombotic complications with IGIV treatment~* Known infection with HIV, HCV or HBV~* Treatment with steroids, immunosuppressive or immunomodulatory drugs~* Planned vaccination during study period~* Pregnant or nursing woman

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Octagam 10% (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).